Prof. Lewis C. Cantley

Prof. Lewis C. Cantley

Professor of Cancer Biology in Medicine and is the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine

Lewis Cantley has made significant advances in cancer research, stemming from his discovery of the signaling pathway phosphoinositide 3-kinase (PI3K) in 1984. His pioneering research has resulted in revolutionary treatments for cancer, diabetes and autoimmune diseases.

The author of over 400 original papers and more than 50 book chapters and review articles, Dr. Cantley is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He graduated summa cum laude with a B.S. in chemistry from West Virginia Wesleyan College (1971) and obtained a Ph.D. in biophysical chemistry from Cornell University (1975).

He conducted postdoctoral research at Harvard University, where he was appointed assistant professor of biochemistry and molecular biology in 1978.

He became a professor of physiology at Tufts University in 1985, but returned to Harvard Medical School as professor of cell biology in 1992.

He became chief of Harvard’s new Division of Signal Transduction, and a founding member of its Department of Systems Biology in 2002.

In 2007, he was appointed director of the Beth Israel Deaconess Cancer Center. He joined the faculty of Weill Cornell Medical College and NewYork-Presbyterian Hospital in 2012

 

ABSTRACT

 

Title: PI 3-Kinase and Cancer Metabolism

Summary: Phosphoinositide 3-Kinase (PI3K) is activated by insulin and other growth factors to mediate cell growth. The PI3K enzyme encoded by the PIK3CA gene is one of the most frequently mutated oncogenes in human cancer.

This same enzyme mediates insulin responses in liver, muscle, fat and other tissues and drugs that inhibit this enzyme have the expected effect of raising serum glucose and insulin levels.

Data will be presented showing that dietary and pharmaceutical interventions that limit elevation of serum insulin improve responses to PI3K inhibitors in mouse models of cancer by preventing insulin-dependent activation of PI3K in tumors.

EACR Free Membership

The IACR is an affiliated national society and its members benefit from full membership of the EACR.

Save The Date

IACR 2023 Conference
Venue: Athlone Radisson Blu Hotel
Dates:
Wed 22/02/2023 – Fri 24/02/2023

Please check back later in the year for more information.

IACR in the Irish Independent

We supported the Cancer 2022 Campaign from @Mediaplanet

Contact Us

8 + 3 =

Latest News

FACEBOOK

Irish Association
for Cancer Research  

9A Coolkill, Sandyford
Dublin 18, Ireland
D18 C1W3

info@iacr.ie
+353 (0)295 8859

Irish Association for Cancer Research (IACR) is a registered charity on the Register of Charitable Organisations, Charities Regulator, 3 George's Dock, IFSC, Dublin 1, D01 X5X0, Ireland.

Registered Charity Number (RCN): 20030117.

©Design by LetterEleven